Molecular diagnostics and treatment of pancreas and bile ducts - A solution to select personalized treatments — Oncompass Medicine
A hasnyálmirigy és az epeutak molekuláris diagnosztikája és kezelése

Knowledge base

Molecular diagnostics and treatment of pancreas and bile ducts

The incidence of pancreatic and biliary malignancies is growing dramatically in developed countries. 

The role of chemotherapy and immunotherapy in the treatment of this disease, which is often diagnosed at an advanced and/or metastatic stage, is coming to the fore. Heritability testing (BRCA mutations) is recommended in all cases of pancreatic tumours, and multigene testing is indicated in advanced and/or metastatic cases before starting therapy.

Therapy based on targetable gene differences detected by molecular profiling resulted in twice as long survival time of pancreatic cancer patients. 

Biliary and pancreatic tumours carry many molecular variations:

Mutations in FGFR, HER-2, BRAF, IDH1, TP53, KRAS, ARID1A, BAP1, PBRM1, SMAD4, FBXW7, MAP-ERK-, and mTOR-, DRD-, FGF- signalling pathway mutations may be additional targeted treatment options.

Immunotherapy may be effective in dMMR/MSI-H, TMB-H cases.

Asco Breakthrough

ASCO Breakthrough Innovations in Oncology

2019 Read more

About us

Our story

2003— —2024

Oncompass Medicine is a Hungarian medical enterprise dealing with the development of decision support and diagnostic medical devices that help the personalized treatment of cancer patients. 

More information